Table 2.
Clinicopathological features of 508 patients subdivided based on the severity of their periodontitis
| Characteristics | No-periodontitis | Mild periodontitis | Severe periodontitis | Edentulous jaw | p |
|---|---|---|---|---|---|
| n = 101 | n = 207 | n = 176 | n = 24 | ||
| (19.90%) | (40.80%) | (34.60%) | (4.70%) | ||
| Sex | 0.701 | ||||
| Female | 14 (13.9%) | 29 (14.0%) | 18 (10.2%) | 3 (12.5%) | |
| Male | 87 (86.1%) | 178 (86.0%) | 158 (89.8%) | 21 (87.5%) | |
| Median age at surgery range | 67 (38–82) | 66 (35–85) | 65 (39–85) | 70 (60–82) | 0.001* |
| Smoking habits | 0.048* | ||||
| Current | 39 (38.6%) | 88 (42.5%) | 95 (54.0%) | 14 (58.3%) | |
| Past | 38 (37.6%) | 74 (35.8%) | 58 (33.0%) | 6 (25.0%) | |
| Never | 18 (17.8%) | 41 (19.8%) | 21 (11.9%) | 4 (16.7%) | |
| Unknown | 6 (6.0%) | 4 (1.9%) | 2 (1.1%) | 0 | |
| Brinkman Index | 0.163 | ||||
| 0 | 18 (17.8%) | 40 (19.3%) | 22 (12.5%) | 4 (16.7%) | |
| Less 400 | 16 (15.9%) | 32 (15.5%) | 23 (13.1%) | 1 (4.2%) | |
| More400 | 60 (59.4%) | 125 (60.4%) | 127 (72.1%) | 19 (79.1%) | |
| Unknown | 7 (6.9%) | 10 (4.8%) | 4 (2.3%) | 0 | |
| Alcohol consumption | 0.751 | ||||
| Habitual | 74 (73.3%) | 165 (79.7%) | 144 (81.8%) | 20 (83.4%) | |
| Opportunity | 6 (5.9%) | 13 (6.3%) | 11 (6.3%) | 2 (8.3%) | |
| Never | 16 (15.8%) | 24 (11.6%) | 16 (9.1%) | 2 (8.3%) | |
| Unknown | 5 (5.0%) | 5 (2.4%) | 5 (2.8%) | 0 | |
| Tumor location | 0.020* | ||||
| Ce | 2 (2.0%) | 2 (1.0%) | 6 (3.4%) | 3 (12.5%) | |
| Ut | 16 (15.8%) | 22 (10.6%) | 27 (15.3%) | 3 (12.5%) | |
| Mt | 54 (53.5%) | 101 (48.8%) | 68 (38.7%) | 11 (45.8%) | |
| Lt | 18 (17.8%) | 58 (28.0%) | 57 (32.4%) | 4 (16.7%) | |
| Ae | 11 (10.9%) | 24 (11.6%) | 18 (10.2%) | 3 (12.5%) | |
| Histologic type | 0.626 | ||||
| SCC | 93 (92.1%) | 189 (91.3%) | 156 (88.6%) | 22 (91.6%) | |
| Adeno | 5 (5.0%) | 16 (7.7%) | 14 (8.0%) | 1 (4.2%) | |
| Others | 3 (2.9%) | 2 (1.0%) | 6 (3.4%) | 1 (4.2%) | |
| Tumor invasion (cT) | 0.203 | ||||
| 1 | 39 (38.6%) | 63 (30.4%) | 51 (29.0%) | 6 (25.0%) | |
| 2 | 14 (13.9%) | 13 (6.2%) | 15 (8.5%) | 4 (16.7%) | |
| 3 | 45 (44.5%) | 125 (60.4%) | 106 (60.2%) | 13 (54.2%) | |
| 4a + 4b | 3 (3.0%) | 6 (3.0%) | 4 (2.3%) | 1 (4.1%) | |
| Lymph node metastasis (cN) | 0.083 | ||||
| 0 | 58 (57.4%) | 87 (42.0%) | 70 (39.8%) | 14 (58.3%) | |
| 1 | 31 (30.7%) | 79 (38.2%) | 64 (36.4%) | 9 (37.5%) | |
| 2 | 9 (8.9%) | 29 (14.0%) | 36 (20.4%) | 1 (4.2%) | |
| 3 | 3 (3.0%) | 10 (4.8%) | 4 (2.3%) | 0 | |
| 4 (M1 lymph +) | 0 | 2 (1.0%) | 2 (1.1%) | 0 | |
| Clinical Stage (UICC7) | 0.169 | ||||
| 1A + 1B | 43 (42.6%) | 60 (29.0%) | 48 (27.3%) | 8 (33.3%) | |
| 2A + 2B | 23 (22.8%) | 41 (19.8%) | 37 (21.0%) | 7 (29.2%) | |
| 3A + 3B + 3C | 35 (34.6%) | 103 (49.8%) | 88 (50.0%) | 9 (37.5%) | |
| 4 | 0 | 3 (1.4%) | 3 (1.7%) | 0 | |
| Neoadjuvant therapy | 0.002* | ||||
| CRT | 28 (27.7%) | 88 (42.5%) | 82 (46.6%) | 4 (16.7%) | |
| Chemo | 3 (3.0%) | 17 (8.2%) | 13 (7.4%) | 1 (4.2%) | |
| RT | 0 | 0 | 1 (0.6%) | 0 | |
| ESD | 8 (7.9%) | 19 (9.2%) | 11 (6.2%) | 1 (4.2%) | |
| Salvage | 4 (4.0%) | 9 (4.4%) | 11 (6.2%) | 4 (16.7%) | |
| Nothing | 58 (57.4%) | 74 (35.7%) | 58 (33.0%) | 14 (58.2%) | |
| Tumor invasion (pT) | 0.163 | ||||
| 0 | 14 (13.9%) | 24 (11.6%) | 21 (11.9%) | 1 (4.2%) | |
| 1 | 50 (49.5%) | 80 (38.6%) | 68 (38.6%) | 7 (29.1%) | |
| 2 | 11 (10.9%) | 17 (8.2%) | 13 (7.4%) | 4 (16.7%) | |
| 3 | 25 (24.7%) | 73 (35.3%) | 64 (36.4%) | 9 (37.5%) | |
| 4a + 4b | 1 (1.0%) | 13 (6.3%) | 10 (5.7%) | 3 (12.5%) | |
| Lymph node metastasis (pN) | 0.177 | ||||
| 0 | 61 (60.4%) | 105 (50.7%) | 110 (62.5%) | 13 (54.2%) | |
| 1 | 31 (30.7%) | 62 (30.0%) | 40 (22.7%) | 9 (37.5%) | |
| 2 | 7 (6.9%) | 30 (14.5%) | 17 (9.7%) | 2 (8.3%) | |
| 3 | 2 (2.0%) | 10 (4.8%) | 9 (5.1%) | 0 | |
| Pathological stage (UICC7) | 0.342 | ||||
| 0 | 10 (9.9%) | 17 (8.2%) | 20 (11.4%) | 1 (4.2%) | |
| 1A + 1B | 39 (38.6%) | 58 (28.0%) | 56 (31.8%) | 7 (29.2%) | |
| 2A + 2B | 34 (33.7%) | 63 (30.4%) | 53 (30.1%) | 6 (25.0%) | |
| 3A + 3B + 3C | 18 (17.8%) | 68 (32.9%) | 47 (26.7%) | 10 (41.6%) | |
| 4 | 0 | 1 (0.5%) | 0 | 0 | |
| Albumin (mg/dl) | 0.176 | ||||
| Normal | 62 (61.4%) | 111 (53.6%) | 85 (48.3%) | 11 (45.8%) | |
| Less than 4.0 | 39 (38.6%) | 96 (46.4%) | 91 (51.7%) | 13 (54.2%) | |
| %VC | 0.031* | ||||
| Over 80% | 97 (96.0%) | 194 (93.7%) | 164 (93.2%) | 19 (79.2%) | |
| Under 80% | 3 (3.0%) | 9 (4.4%) | 10 (5.7%) | 5 (20.8%) | |
| Unknown | 1 (1.0%) | 4 (1.9%) | 2 (1.1%) | 0 | |
| FEV1.0% | 0.42 | ||||
| Over 70% | 77 (76.2%) | 162 (78.3%) | 142 (80.7%) | 15 (62.5%) | |
| Under 70% | 23 (22.8%) | 41 (19.8%) | 32 (18.2%) | 9 (37.5%) | |
| Unknown | 1 (1.0%) | 4 (1.9%) | 2 (1.1%) | 0 | |
| Operation type | 0.82 | ||||
| Transthoracic | 51 (50.5%) | 114 (55.1%) | 98 (55.7%) | 14 (58.3%) | |
| Thoracoscopic | 50 (49.5%) | 93 (44.9%) | 78 (44.3%) | 10 (41.7%) | |
| Operation time | 0.13 | ||||
| Over 538 min | 56 (55.4%) | 119 (57.5%) | 119 (67.6%) | 14 (58.3%) | |
| Under 538 min | 45 (44.6%) | 88 (42.5%) | 57 (32.4%) | 10 (41.7%) | |
| Operation bleeding | 0.541 | ||||
| Over 692 ml | 24 (23.8%) | 51 (24.6%) | 49 (27.8%) | 5 (20.8%) | |
| Under 692 ml | 76 (75.2%) | 156 (75.4%) | 127 (72.2%) | 19 (79.2%) | |
| Unknown | 1 (1.0%) | 0 | 0 | 0 |
* Considered significant